Short answer
ANAPTYSBIO, INC (ANAB) filed an 8-K current report with the SEC on April 20, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Spin-off separates AnaptysBio’s royalty-management business from First Tracks’ autoimmune and inflammatory drug pipeline.
ANAPTYSBIO, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Spin-off separates AnaptysBio’s royalty-management business from First Tracks’ autoimmune and inflammatory drug pipeline
- First Tracks receives $100.0 million cash, development assets, and potential Vanda milestones up to $35.0 million
- AnaptysBio retains dostarlimab and imsidolimab royalties, including GSK and Vanda collaboration rights and related liabilities
- Each company assumes liabilities tied to its post-spin-off business, with reciprocal indemnification for breaches, taxes, and shareholder claims
- Transition arrangements, delayed transfers, and commingled contracts may require coordination for up to 24 months after distribution
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Spin-off completed April 20, 2026 under the Separation and Distribution Agreement
- Transaction separates specified assets or operations from AnaptysBio, changing the company’s strategic and financial profile
- Investors should review the Explanatory Note for the businesses, liabilities, and distribution mechanics affected
Item 5.02 · Departure/Election of Directors or Officers
- Four directors resigned between April 20–23, 2026, reflecting board reconstitution tied to the Spin-Off
- Paul Lizzul ceased serving as Chief Medical Officer and joined First Tracks Biotherapeutics in the same role
- CEO Daniel Faga transitioned to consultant CEO through at least January 15, 2027
- Faga’s equity awards continue vesting, with potential accelerated vesting if terminated before January 15, 2027
- Dennis Mulroy and Eric Loumeau’s separations became effective April 20, 2026
Item 8.01 · Other Events
- Pro forma financial information pending, due by amendment within four business days after the Spin-Off
- Separation and Distribution Agreement formalizes Spin-Off terms between AnaptysBio and First Tracks Biotherapeutics
- Transition Services Agreement indicates ongoing operational support between the two companies after separation
- Redacted deal provisions and omitted schedules limit visibility into complete transaction economics
- April 20, 2026 press release provides additional transaction context for investors
Item EX-99.1 · Exhibit EX-99.1
- Completed taxable spin-off of First Tracks Biotherapeutics, distributing one TRAX share per ANAB share held April 6, 2026
- ANAB now exclusively manages royalty collaborations for Jemperli with GSK and imsidolimab with Vanda
- Launches virtual model with approximately $140–$145 million net cash and limited FTEs
- Greater than 95% EBIT margin target highlights potentially high cash conversion from royalties
- ANAB remains Nasdaq-listed under ANAB; First Tracks begins regular-way trading under TRAX
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ANAPTYSBIO, INC 8-K filings
Get the next ANAB 8-K as it lands
Follow ANAB for push alerts, or ask the research agent what this filing means.